Quick Take
Axcella Health (AXLA) intends to raise $75 million from the sale of its common stock in a U.S. IPO, per an amended registration statement.
The company is advancing a pipeline of treatment candidates primarily for liver disease conditions.
Given the uncertainties with the firm’s regulatory approach, lack of IND Phase 1 safety trial results, pricey valuation, and lack of existing investor support for the IPO, I'll be sitting this IPO out.
Company & Technology
Cambridge, Massachusetts-based Axcella was founded in 2008 to develop new disease-specific endogenous amino acid profiles which